{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-224253","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2023-08-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.417688+00:00","generated_at":"2026-06-11T02:03:33.952424+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Tango Therapeutics director Aaron Davis resigns; John Ketchum appointed to board","bullets":["Aaron Davis resigned from board effective Aug 28, 2023; no disagreement with management.","John Ketchum appointed as Class III director effective Aug 29, 2023; will stand for election at 2024 annual meeting.","Ketchum receives option for 60,000 shares at $7.19, RSU for 10,000 shares, and $40k annual retainer.","Ketchum deemed independent under Nasdaq rules; no committee assignments yet."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-224253","json":"https://secwatch.observer/filing/0001193125-23-224253.json","markdown":"https://secwatch.observer/filing/0001193125-23-224253.md","text":"https://secwatch.observer/filing/0001193125-23-224253.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000119312523224253/0001193125-23-224253-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000119312523224253/d532996d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T02:03:33.952424+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65dacfee7f","claim":"Aaron Davis resigned as Member of the Board of Directors, Class III director at Tango Therapeutics, Inc..","evidence_excerpt":"On August 28, 2023, Aaron Davis, a member of the Board of Directors of Tango Therapeutics, Inc. (the “Company”), serving as a Class III director, notified the Company that he is resigning from the Company’s Board of Directors (the “Board”), effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312523224253/0001193125-23-224253-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of the Board of Directors, Class III director"}],"fact_type":"executive_change"},{"claim_id":"6ac13f1fd2","claim":"John Ketchum was appointed as Director (Class III) at Tango Therapeutics, Inc..","evidence_excerpt":"Effective August 29, 2023, the Board appointed John Ketchum as a director of the Company to fill the newly created vacancy on the Board resulting from Mr. Davis’s resignation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312523224253/0001193125-23-224253-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director (Class III)"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}